Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

of Plicera pending the results of the ongoing Phase 2 trial.

AT2220 (1-deoxynojirimycin HCl) for the treatment of Pompe Disease

As previously reported, the Company suspended enrollment for the Phase 2 clinical trial of its investigational drug AT2220 for the treatment of Pompe Disease and received notice from the U.S. Food and Drug Administration (FDA) that the trial is on clinical hold.

The Company continues to work closely with the FDA to determine appropriate next steps for advancing the development of AT2220 and expects to provide guidance on this progress over the upcoming months.

Additionally, Amicus continues to be encouraged with its preclinical studies with AT2220 in combination with ERT. As previously announced, the Company expects to report additional data from these activities throughout the remainder of 2009.

Preclinical Chaperone Programs

Amicus continues to invest in research to assess the potential for applying its versatile chaperone technology platform to the treatment of a broad range of human genetic diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders.

Appointment of New Director

The Company announced today the election of James Barrett, Ph.D., to its Board of Directors. Dr. Barrett currently serves as General Partner of New Enterprise Associates (NEA), the Company's single largest shareholder, where he specializes in biotechnology and works with members of NEA's healthcare investment group on medical devices, healthcare information systems and healthcare services companies. Prior to joining NEA in 2001, Dr. Barrett served as Founder, Chairman and CEO of Sensors for Medicine and Science (1997 - 2001
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... , September 22, 2014 ... the addition of the "Global Biotechnology Reagents ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents ... to a system to detect and examine another ... generally used in laboratories to prepare, collect, and ...
(Date:9/22/2014)... it is to stop bleeding, are very simple. They ... the physical environment around them, researchers at Emory and ... with greater stiffness by increasing their stickiness, the degree ... components of the clotting system, the researchers found. , ... in that they are able to sense the physical ...
Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3Platelets modulate clotting behavior by 'feeling' their surroundings 2
... Texas, Jan. 5, 2012  Healthpoint Biotherapeutics today announced that ... Robert Bancroft, Executive Vice President, Strategic and Commercial Development, ... products and its R&D pipeline at the upcoming J.P. ... January 9th, at 9:30 am (PST) at the Westin ...
... Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis company, today ... presentation at the 5 th Annual OneMedForum San ... Francisco, Calif., January 9-12, 2012. The company ... beginning at 10:00 a.m. Pacific Time.  The presentation will ...
... 5, 2012  ZyGEM Corp. Ltd., a developer and ... DNA and other nucleic acids, and the US ... today announced the signing of a Cooperative Research ... simplified sample processing solutions for biothreat agents.  The ...
Cached Biology Technology:WaferGen to Present Corporate Overview at 5th Annual OneMedForum San Francisco 2012 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 2ZyGEM and USAMRIID Sign CRADA for Development of Simplified Sample Processing Solutions for Biothreat Agents 3
(Date:9/23/2014)... times more carbon than the atmosphere and small ... big effect on atmospheric greenhouse gas concentrations. A ... Change concludes that climate warming does not ... carbon storage, despite increases in ecosystem productivity. ... Research Ecologist Dr. Christian Giardina, with the agency,s ...
(Date:9/23/2014)... temperature on insects to predict how climate change will ... shows for the first time that insects, fear of ... fast they grow. , "In other words, it,s less ... that shape the growth, survival and distribution of insects." ... an Arctic postdoctoral researcher at Dartmouth. , The ...
(Date:9/23/2014)... Eureka Therapeutics, Inc. announced today that the Company has ... new funding will be used to expand the Company,s ... clinical development. New investor Yuan Capital led the round, ... including Acorn Campus Ventures, Suma Venture and Harbinger Venture ... and development of fully-human antibodies engineered to mimic the ...
Breaking Biology News(10 mins):Study helps assess impact of temperature on belowground soil decomposition 2Insects' fear limits boost from climate change, Dartmouth study shows 2
... SAN DIEGO, Calif. (March 10, 2009)Attempts to treat ... patients with below-the-knee angioplasty are still thwarted by ... site of angioplasty or stenting), the need for ... disease, leading to tissue death (gangrene) and amputation. ...
... SAN DIEGO, Calif. (March 10, 2009)The use of common ... (ABI)along with traditional risk scoring systemssuch as the Framingham ... in thousands of individuals who are not originally thought ... say researchers at the Society of Interventional Radiology,s 34th ...
... March 9 Explorations Group Inc. (OTC Bulletin ... letter of intent to acquire Daniel R. Smith & Associates, ... total of $4.2 million to be paid in a combination ... Intent, EXGI President David Coriaty stated "the acquisition of DRSA ...
Cached Biology News:Promising 3-year data: Saving limbs with drug-eluting stents 2Promising 3-year data: Saving limbs with drug-eluting stents 3Simple test helps predict heart attack risk 2Simple test helps predict heart attack risk 3Explorations Group Announces Letter of Intent to Acquire Specialty Lighting Company 2
...
Contains L-glutamine...
... 140kDa GenBank Accession ... amino acids 926-941 (DKKVKPPFIPTIRGRE) of human PRK2. ... Quality Assurance Routinely evaluated by ... Stability 1 year at ...
...
Biology Products: